Ayala Pharmaceuticals Inc (ADXS)

[samk]

tx_farmer, thanks for posting this great interview!

A couple of things stand out to picture ADXS future:

"Immunotherapy will become the backbone for a multi-modality approach to treat advanced cancers. With the superior ability of immunotherapies to eliminate residual cancers following frontline treatment modalities of chemotherapy and radiation, it will be key in preventing disease progression and recurrence. With checkpoint inhibitors and therapeutic vaccines, such as axalimogene filolisbac which is being tested in phase 3 studies for advanced cervical cancer, there are significant changes coming to maintenance therapy and the adjuvant therapy setting, and these immunotherapies just as easily have the potential to be added to the standard of care alongside frontline treatments, too. There’s certainly a paradigm shift coming."

"In addition, we have seen strong data suggesting how our lead product candidate, axalimogene filolisbac, will work well with Merck’s KEYTRUDA® and AstraZeneca’s duvalumab." - now we know
that with Merck and Astra we are on the right track too...